обновленная версия от 04/10/2021 Информация о введении вакцин

Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г.

24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac, the Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorisation for the vaccine (see scenario #1). As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #

24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the COVID-19 Vaccine BIBP/ Sinopharm, the Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorization for the vaccine (see scenario #1) and the specification is 0.5ml/dose, 1 dose/vial; or 2 doses/vial; or 5 doses/vial. As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1

This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to expect following vaccination: ...

July 2021

Вакцина против COVID-19 CoronaVac производства компании Sinovac (Sinovac-CoronaVac) July 2021

временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021��

FEY ENFOMASYON POU MOUN K’AP RESEVWA AVEK MOUN K’AP BAY SWEN OTORIZASYON POU ITILIZASYON IJANS (EUA) POU VAKSIN MODERNA COVID-19 POU ANPECHE CORONAVIRUSDISEASE 2019 (COVID-19) NAN PERSONN 18 ANE AK PI GRA

Estas orientaciones provisionales se han elaborado a partir de las recomendaciones que hizo el Grupo de Expertos de la OMS en Asesoramiento Estratégico en materia de inmunización (SAGE) en su reunión extraordinaria del 15 de marzo de 2021 [1], y que fueron actualizadas en su reunión extraordinaria del 27 de mayo de 2021 [2]